Floatz logo

Abt-530

Human Immunodeficiency Virus Infection

AbbViePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Human Immunodeficiency Virus Infection cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
Efavirenz
The Cleveland Clinic
Phase 4BBB
Ganciclovir
Phase 4BBB
RITONAVIR
Giovanni Di Perri
Phase 4BBB

View all 50 →

Same molecule, other indications

Abt-530 is also rated in:

hepatitis C virus infectionDormant
A
Indicative ·
84 / 100
View asset →
chronic hepatitis C virus infectionDormant
A
Indicative ·
80 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →